Science, industry, and politics at the FDABMJ 2003; 327 doi: https://doi.org/10.1136/bmjusa.02110001 (Published 19 November 2003) Cite this as: BMJ 2003;327:E160
From BMJ USA 2002;November:589
In this issue, the Australian journalist Ray Moynihan reports on the FDA decision to reintroduce alosetron (Lotronex) for irritable bowel syndrome despite serious side effects (BMJ USA p 633). He asserts that the FDA looked the other way, ignoring warnings from its advisory committees and FDA staff, under pressure from private industry and advocacy groups.
The cover photo of the September 14 BMJ, in which his article first appeared, showed the FDA building in Rockville, Maryland, above the provocative caption, “Who owns the FDA?” A news report in that issue quoted a former FDA consultant: “[the agency …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial